141 related articles for article (PubMed ID: 16495075)
1. Photodynamic treatment (ALA-PDT) suppresses the expression of the oncogenic Bcr-Abl kinase and affects the cytoskeleton organization in K562 cells.
Pluskalová M; Peslová G; Grebenová D; Halada P; Hrkal Z
J Photochem Photobiol B; 2006 Jun; 83(3):205-12. PubMed ID: 16495075
[TBL] [Abstract][Full Text] [Related]
2. The effect of 5-aminolevulinic acid-based photodynamic treatment (PDT) on nucleoli of leukemic granulocytic precursors represented by K562 blastic cells in vitro.
Smetana K; Pluskalová M; Marinov Y; Hrkal Z
Med Sci Monit; 2004 Nov; 10(11):BR405-9. PubMed ID: 15507844
[TBL] [Abstract][Full Text] [Related]
3. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y
FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464
[TBL] [Abstract][Full Text] [Related]
4. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
[TBL] [Abstract][Full Text] [Related]
5. The Bcr-Abl kinase regulates the actin cytoskeleton via a GADS/Slp-76/Nck1 adaptor protein pathway.
Preisinger C; Kolch W
Cell Signal; 2010 May; 22(5):848-56. PubMed ID: 20079431
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90.
Wu LX; Xu JH; Huang XW; Zhang KZ; Wen CX; Chen YZ
Acta Pharmacol Sin; 2006 Jun; 27(6):694-9. PubMed ID: 16723087
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
Pytel D; Wysocki T; Majsterek I
Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of bcr-abl and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes.
Ohba H; Zhelev Z; Bakalova R; Ewis A; Omori T; Ishikawa M; Shinohara Y; Baba Y
Cancer; 2004 Sep; 101(6):1390-403. PubMed ID: 15368327
[TBL] [Abstract][Full Text] [Related]
10. [Effects of anti-ABL tyrosine kinase intrabody on the growth of K562 cells in nude mice].
Xu D; Song JM; Hu Y; Guo H; Cao DJ; Wang P; Liu H; Zhao CH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Feb; 24(1):11-4. PubMed ID: 12905832
[TBL] [Abstract][Full Text] [Related]
11. Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells.
Zhang KZ; Xu JH; Huang XW; Wu LX; Su Y; Chen YZ
Acta Pharmacol Sin; 2007 Jan; 28(1):105-10. PubMed ID: 17184589
[TBL] [Abstract][Full Text] [Related]
12. [Role of calcium signal in apoptosis and protective mechanism of colon cancer cell line SW480 in response to 5-aminolevulinic acid-photodynamic therapy].
Zheng JH; Shi D; Zhao Y; Chen ZL
Ai Zheng; 2006 Jun; 25(6):683-8. PubMed ID: 16764761
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
15. [Effect of hydroxyurea combined with interferon-alpha on growth and apoptosis-related oncogene expression of K562 cells].
Chen H; Luo Z; Luo S
Zhonghua Yi Xue Za Zhi; 2000 Aug; 80(8):606-9. PubMed ID: 11798827
[TBL] [Abstract][Full Text] [Related]
16. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Lothstein L; Savranskaya L; Sweatman TW
Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
[TBL] [Abstract][Full Text] [Related]
17. [The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine].
Sun JR; Zhang XH; He ZW; Gu Y; Yu YZ; Fang YM; Lü QH; Dong QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2246-51. PubMed ID: 17064567
[TBL] [Abstract][Full Text] [Related]
18. Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK.
Brózik A; Casey NP; Hegedus C; Bors A; Kozma A; Andrikovics H; Geiszt M; Német K; Magócsi M
Ann N Y Acad Sci; 2006 Dec; 1090():344-54. PubMed ID: 17384279
[TBL] [Abstract][Full Text] [Related]
19. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model.
Lin F; Monaco G; Sun T; Liu J; Lin H; Stephens C; Belmont J; Arlinghaus RB
Oncogene; 2001 Apr; 20(15):1873-81. PubMed ID: 11313935
[TBL] [Abstract][Full Text] [Related]
20. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
